Development of selective human DHODH inhibitors for antiviral therapy

Vol 2, 2022 - 153240
Poster
Favoritar este trabajo
¿Cómo citar este artículo?
Resúmenes

The human dihydroorotate dehydrogenase (hDHODH), a crucial flavin-dependent mitochondrial enzyme in the de novo pyrimidine synthesis, has been considered a promising therapeutic target to tackle tumor progression and viral infection since infectious viruses such as the SARS-CoV-2, a current global threat to public health,
require host factors including hDHODH for viral replication. Therefore, the development of selective hDHODH inhibitors as host-targeting antivirals (HTAs) may lead to effective broad-spectrum antiviral agents with minimal drug resistance induction as an alternative to Leflunomide, Teriflunomide, and Brequinar, which have known efficacy and toxicity issues. Based on the interaction profile of quinone-based molecules in the ubiquinone binding site of hDHODH, we rationalized that the heterocyclic scaffolds quinazolinone and quinoxalinone
could mimic important hydrogen-bonding interactions. Two linear synthetic routes were successfully established to obtain functionalized quinazolinones and quinazolinones which are under evaluation via enzymatic assays with hDHODH.

¡Comparte tus ideas o preguntas con los autores!

¿Sabías que el mayor estímulo en el desarrollo científico y cultural es la curiosidad? ¡Deje sus preguntas o sugerencias al autor!

Inicia sesión para interactuar

¿Tiene alguna pregunta o sugerencia? ¡Comparte tus comentarios con los autores!

Instituciones
  • 1 Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP), Universidade de São Paulo (USP)
  • 2 Universidade de São Paulo
Eje Temático
  • 2. Medicinal Chemistry of Synthetic Compounds
Palabras Clave
drug design
Human DHODH
antiviral activity
Quinazolinones
Quinoxalinones